Edition:
India

Moleculin Biotech Inc (MBRX.OQ)

MBRX.OQ on NASDAQ Stock Exchange Capital Market

1.83USD
1:30am IST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.83
Open
$1.83
Day's High
$1.88
Day's Low
$1.80
Volume
19,570
Avg. Vol
136,832
52-wk High
$3.74
52-wk Low
$0.71

Chart for

About

Moleculin Biotech, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML).... (more)

Overall

Beta: --
Market Cap(Mil.): $49.84
Shares Outstanding(Mil.): 20.26
Dividend: --
Yield (%): --

Financials

  MBRX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.46 -- --
ROI: -35.48 14.84 14.38
ROE: -36.21 16.34 16.07

BRIEF-Moleculin Biotech Inc - Has Been Able To Show Promising Tumor Suppression Activity With Its Inhibitor Of Glycolysis, Wp1122

* MOLECULIN BIOTECH INC - HAS BEEN ABLE TO SHOW PROMISING TUMOR SUPPRESSION ACTIVITY WITH ITS INHIBITOR OF GLYCOLYSIS, WP1122 Source text for Eikon: Further company coverage:

07 Feb 2018

BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor

* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR

10 Jan 2018

BRIEF-Moleculin Announces Polish Approval For Leukemia Clinical Trial

* MOLECULIN ANNOUNCES POLISH APPROVAL FOR LEUKEMIA CLINICAL TRIAL

21 Dec 2017

BRIEF-Moleculin Biotech Says Co Was Informed That Investigational NDA For Phase I Trial Of WP1066 Has Been Allowed By FDA

* MOLECULIN BIOTECH SAYS ON NOV 29, CO WAS INFORMED THAT INVESTIGATIONAL NDA FOR PHASE I TRIAL OF WP1066 HAS BEEN ALLOWED BY FDA - SEC FILING Source text: [http://bit.ly/2jcVpeo] Further company coverage:

04 Dec 2017

BRIEF-Moleculin Biotech Q3 loss per share $0.14‍​

* Moleculin Biotech Inc reports financial results for the third quarter ended september 30, 2017

14 Nov 2017

BRIEF-Moleculin appoints Sandra Silberman as chief medical officer

* Moleculin appoints Dr. Sandra Silberman as chief medical officer -- new products Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

* Moleculin announces MD Anderson has filed an IND with the FDA on its drug WP1066 for the treatment of brain tumors

01 Nov 2017

Earnings vs. Estimates